386 related articles for article (PubMed ID: 10029430)
1. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
Feldkamp MM; Angelov L; Guha A
Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
[TBL] [Abstract][Full Text] [Related]
2. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.
Guha A; Lau N; Huvar I; Gutmann D; Provias J; Pawson T; Boss G
Oncogene; 1996 Feb; 12(3):507-13. PubMed ID: 8637706
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 1: piecing the puzzle together.
Feldkamp MM; Gutmann DH; Guha A
Can J Neurol Sci; 1998 Aug; 25(3):181-91. PubMed ID: 9706718
[TBL] [Abstract][Full Text] [Related]
4. [Characterization of the neurofibromatosis type 1 gene and neurofibromin's role in cells].
Sakai A
Nihon Rinsho; 2000 Jul; 58(7):1426-9. PubMed ID: 10921317
[TBL] [Abstract][Full Text] [Related]
5. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
8. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
9. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
10. [From gene to disease; neurofibromatosis type 1].
de Goede-Bolder A; Cnossen MH; Dooijes D; van den Ouweland AM; Niermeijer MF
Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1736-8. PubMed ID: 11572174
[TBL] [Abstract][Full Text] [Related]
11. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
12. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
Ratner N; Miller SJ
Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
14. Ras-GTP regulation is not altered in cultured melanocytes with reduced levels of neurofibromin derived from patients with neurofibromatosis 1 (NF1).
Griesser J; Kaufmann D; Eisenbarth I; Bäuerle C; Krone W
Biol Chem Hoppe Seyler; 1995 Feb; 376(2):91-101. PubMed ID: 7794530
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic targets for neurofibromatosis type 1.
Walker JA; Upadhyaya M
Expert Opin Ther Targets; 2018 May; 22(5):419-437. PubMed ID: 29667529
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in the neurofibromatosis 1 gene in human tumors.
Li Y; Bollag G; Clark R; Stevens J; Conroy L; Fults D; Ward K; Friedman E; Samowitz W; Robertson M
Cell; 1992 Apr; 69(2):275-81. PubMed ID: 1568247
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetics of neurofibromatosis type 1].
Suzuki H; Takahashi K; Shibahara S
Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
[TBL] [Abstract][Full Text] [Related]
18. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
19. Gene-targeted deletion of neurofibromin enhances the expression of a transient outward K+ current in Schwann cells: a protein kinase A-mediated mechanism.
Xu Y; Chiamvimonvat N; Vázquez AE; Akunuru S; Ratner N; Yamoah EN
J Neurosci; 2002 Nov; 22(21):9194-202. PubMed ID: 12417644
[TBL] [Abstract][Full Text] [Related]
20. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
